Chonluten
Chonluten / T-34 (Glu-Asp-Gly / EDG Tripeptide; bronchoalveolar bioregulator)
Khavinson family bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Synthetic tripeptide developed for bronchial mucosa and alveolar regulation; often paired with Bronchogen for respiratory protocols. Most efficacy data is from one Russian lab; independent Western replication is essentially absent.
At a glance
- Routes
- SubQ · Oral
- Vial sizes
- 20 mg
- Evidence base
- 1 study 1 preclinical
Mechanism
Per the Khavinson 'short-peptide bioregulator' hypothesis, EDG is proposed to enter bronchopulmonary epithelial cells and modulate gene expression: modulation of stress response genes (c-Fos, HSP70), induction of antioxidant enzymes (SOD), and inflammatory mediators (COX-2, TNF-α) documented in bronchial cell cultures. Mechanism is contested in mainstream pharmacology because tripeptides are normally degraded in serum within minutes. Reported preclinical effects: improved mucociliary clearance markers and restoration of respiratory epithelial barrier integrity in aged tissue models.
Dosing
No standardized human dosing has been established. Every catalogued study for Chonluten is preclinical or a literature review. Amounts used in animal models do not translate directly to humans.
Published evidence
-
In vitro 2014
Tripeptide EDG (Chonluten / T-34) regulates bronchial epithelial gene expression
EDG modulated stress response genes and antioxidant enzymes in bronchial cell cultures.
Reported side effects
- Long-term safety unverified outside Russia
- Unknown Mild · Khavinson group reports a clean AE profile; no Western replication.
Interactions
-
Bronchogen Synergy
Both Khavinson respiratory peptides: Chonluten targets mucosa/alveolar; Bronchogen targets bronchial epithelium.
Reconstitution and storage
20 mg vial; 2-5 mL BAC water. At 4 mg/mL, 100 mcg = 0.025 mL.
Lyophilized: room temp short-term, refrigerate for >30 days. Reconstituted: refrigerate, use within 30 days.